{"id":"cyclobenzaprine","rwe":[{"pmid":"41889332","year":"2026","title":"Superior Oblique Myokymia Treated with Cyclobenzaprine.","finding":"","journal":"The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques","studyType":"Clinical Study"},{"pmid":"41822869","year":"2026","title":"Cyclobenzaprine Reimagined: Clinical Insights Into Tonmya for Fibromyalgia.","finding":"","journal":"The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians","studyType":"Clinical Study"},{"pmid":"41749492","year":"2026","title":"Single-Dose Pharmacokinetic Assessment of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open-Label Studies in Healthy Volunteers.","finding":"","journal":"Clinical pharmacology in drug development","studyType":"Clinical Study"},{"pmid":"41730795","year":"2026","title":"Maternal and Pediatric Precision in Therapeutic Knowledge Portal (MPRINT-KP): Landscape Analysis of Pharmacology Research in Maternal and Pediatric Patient Populations.","finding":"","journal":"Pharmacotherapy","studyType":"Clinical Study"},{"pmid":"30000455","year":"2006","title":"Cyclobenzaprine.","finding":"","journal":"","studyType":"Clinical Study"}],"_fda":{"id":"45378d8a-334e-5f49-e063-6394a90afcaa","set_id":"00b20a8c-debd-e930-e063-6394a90a7ed0","openfda":{"unii":["0VE05JYS2P"],"route":["ORAL"],"rxcui":["828320"],"spl_id":["45378d8a-334e-5f49-e063-6394a90afcaa"],"brand_name":["CYCLOBENZAPRINE HYDROCHLORIDE"],"spl_set_id":["00b20a8c-debd-e930-e063-6394a90a7ed0"],"package_ndc":["60760-766-30","60760-766-15","60760-766-04","60760-766-90"],"product_ndc":["60760-766"],"generic_name":["CYCLOBENZAPRINE HYDROCHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CYCLOBENZAPRINE HYDROCHLORIDE"],"manufacturer_name":["ST. MARY'S MEDICAL PARK PHARMACY"],"application_number":["ANDA208170"],"original_packager_product_ndc":["72888-012"]},"version":"3","warnings":["WARNINGS Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with cyclobenzaprine hydrochloride when used in combination with other drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tramadol, bupropion, meperidine, verapamil, or (MAO) inhibitors. The concomitant use of cyclobenzaprine hydrochloride with MAO inhibitors is contraindicated (see CONTRAINDICATIONS ). Serotonin syndrome symptoms may include mental status changes (e.g., confusion, agitation, hallucinations), autonomic instability (e.g., diaphoresis, tachycardia, labile blood pressure, hyperthermia), neuromuscular abnormalities (e.g., tremor, ataxia, hyperreflexia, clonus, muscle rigidity), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Treatment with cyclobenzaprine hydrochloride and any concomitant serotonergic agents should be discontinued immediately if the above reactions occur and supportive symptomatic treatment should be initiated. If concomitant treatment with cyclobenzaprine hydrochloride and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dose increases (see PRECAUTIONS: Drug Interactions ). Cyclobenzaprine is closely related to the tricyclic antidepressants, e.g., amitriptyline and imipramine. In short term studies for indications other than muscle spasm associated with acute musculoskeletal conditions, and usually at doses somewhat greater than those recommended for skeletal muscle spasm, some of the more serious central nervous system reactions noted with the tricyclic antidepressants have occurred (see WARNINGS , below, and ADVERSE REACTIONS ). Tricyclic antidepressants have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke. Cyclobenzaprine may enhance the effects of alcohol, barbiturates, and other CNS depressants."],"overdosage":["OVERDOSAGE Although rare, deaths may occur from overdosage with cyclobenzaprine. Multiple drug ingestion (including alcohol) is common in deliberate cyclobenzaprine overdose. As management of overdose is complex and changing, it is recommended that the physician contact a poison control center for current information on treatment . Signs and symptoms of toxicity may develop rapidly after cyclobenzaprine overdose; therefore, hospital monitoring is required as soon as possible. The acute oral LD 50 of cyclobenzaprine is approximately 338 and 425 mg/kg in mice and rats, respectively. Manifestations The most common effects associated with cyclobenzaprine overdose are drowsiness and tachycardia. Less frequent manifestations include tremor, agitation, coma, ataxia, hypertension, slurred speech, confusion, dizziness, nausea, vomiting, and hallucinations. Rare but potentially critical manifestations of overdose are cardiac arrest, chest pain, cardiac dysrhythmias, severe hypotension, seizures, and neuroleptic malignant syndrome. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of cyclobenzaprine toxicity. Other potential effects of overdosage include any of the symptoms listed under ADVERSE REACTIONS. Management General As management of overdose is complex and changing, it is recommended that the physician contact a poison control center for current information on treatment. In order to protect against the rare but potentially critical manifestations described above, obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line and initiate gastric decontamination. Observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at any time during this period, extended monitoring is required. Monitoring of plasma drug levels should not guide management of the patient. Dialysis is probably of no value because of low plasma concentrations of the drug. Gastrointestinal Decontamination All patients suspected of an overdose with cyclobenzaprine should receive gastrointestinal decontamination. This should include large volume gastric lavage followed by activated charcoal. If consciousness is impaired, the airway should be secured prior to lavage and emesis is contraindicated. Cardiovascular A maximal limb-lead QRS duration of ≥ 0.10 seconds may be the best indication of the severity of the overdose. Serum alkalinization, to a pH of 7.45 to 7.55, using intravenous sodium bicarbonate and hyperventilation (as needed), should be instituted for patients with dysrhythmias and/or QRS widening. A pH > 7.60 or a pCO 2 < 20 mmHg is undesirable. Dysrhythmias unresponsive to sodium bicarbonate therapy/hyperventilation may respond to lidocaine, bretylium or phenytoin. Type 1A and 1C antiarrhythmics are generally contraindicated (e.g., quinidine, disopyramide, and procainamide). CNS In patients with CNS depression, early intubation is advised because of the potential for abrupt deterioration. Seizures should be controlled with benzodiazepines or, if these are ineffective, other anticonvulsants (e.g., phenobarbital, phenytoin). Physostigmine is not recommended except to treat life-threatening symptoms that have been unresponsive to other therapies, and then only in close consultation with a poison control center. Psychiatric Follow-up Since overdosage is often deliberate, patients may attempt suicide by other means during the recovery phase. Psychiatric referral may be appropriate. Pediatric Management The principles of management of child and adult overdosages are similar. It is strongly recommended that the physician contact the local poison control center for specific pediatric treatment."],"description":["DESCRIPTION Cyclobenzaprine hydrochloride, USP is a tricyclic amine salt which is white to off white, odourless, crystalline powder with the molecular formula C 20 H 21 N • HCl and a molecular weight of 311.9. It has a melting point of 217°C, and a pKa of 8.47 at 25°C. It is freely soluble in water, in alcohol and in methanol, sparingly soluble in isopropanol, slightly soluble in chloroform and in methylene chloride, insoluble in n-hexane. If aqueous solutions are made alkaline, the free base separates. Cyclobenzaprine hydrochloride is designated chemically as 3-(5H -dibenzo[a,d] cyclohepten-5-ylidene)- N,N -dimethyl-1-propanamine hydrochloride, and has the following structural formula: Cyclobenzaprine hydrochloride tablets, USP are available as 5 mg, 7.5 mg and 10 mg tablets for oral administration. Each 5 mg, 7.5 mg and 10 mg tablet contains cyclobenzaprine hydrochloride and the following inactive ingredients: crospovidone, hypromellose, lactose anhydrous, macrogol, magnesium stearate, polysorbate 80, pregelatinized starch, silicified microcrystalline cellulose, titanium dioxide. The tablets of 5 mg and 10 mg also contain D&C Yellow #10 Aluminum Lake and FD&C Yellow #6 Sunset Yellow FCF Aluminum Lake. In addition, the 5 mg tablets contain FD&C Blue #2/INDIGO Carmine Aluminum Lake. Image"],"precautions":["PRECAUTIONS General Because of its atropine-like action, cyclobenzaprine should be used with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic medication. Impaired Hepatic Function The plasma concentration of cyclobenzaprine is increased in patients with hepatic impairment (see CLINICAL PHARMACOLOGY: Pharmacokinetics: Hepatic Impairment ). These patients are generally more susceptible to drugs with potentially sedating effects, including cyclobenzaprine. Cyclobenzaprine hydrochloride should be used with caution in subjects with mild hepatic impairment starting with a 5 mg dose and titrating slowly upward. Due to the lack of data in subjects with more severe hepatic insufficiency, the use of cyclobenzaprine in subjects with moderate to severe impairment is not recommended. Information for Patients Cyclobenzaprine, especially when used with alcohol or other CNS depressants, may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. In the elderly, the frequency and severity of adverse events associated with the use of cyclobenzaprine, with or without concomitant medications, is increased. In elderly patients, cyclobenzaprine hydrochloride should be initiated with a 5 mg dose and titrated slowly upward. Patients should be cautioned about the risk of serotonin syndrome with the concomitant use of cyclobenzaprine hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil or MAO inhibitors. Patients should be advised of the signs and symptoms of serotonin syndrome, and be instructed to seek medical care immediately if they experience these symptoms (see WARNINGS and PRECAUTIONS: Drug Interactions ). Drug Interactions Cyclobenzaprine may have life-threatening interactions with MAO inhibitors (see CONTRAINDICATIONS ). Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil or MAO inhibitors. If concomitant treatment with cyclobenzaprine hydrochloride and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dose increases (see WARNINGS ). Cyclobenzaprine may enhance the effects of alcohol, barbiturates, and other CNS depressants. Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds. Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol. Carcinogenesis, Mutagenesis, Impairment of Fertility In rats treated with cyclobenzaprine for up to 67 weeks at doses of approximately 5 to 40 times the maximum recommended human dose, pale, sometimes enlarged, livers were noted and there was a dose-related hepatocyte vacuolation with lipidosis. In the higher dose groups this microscopic change was seen after 26 weeks and even earlier in rats which died prior to 26 weeks; at lower doses, the change was not seen until after 26 weeks. Cyclobenzaprine did not affect the onset, incidence or distribution of neoplasia in an 81-week study in the mouse or in a 105-week study in the rat. At oral doses of up to 10 times the human dose, cyclobenzaprine did not adversely affect the reproductive performance or fertility of male or female rats. Cyclobenzaprine did not demonstrate mutagenic activity in the male mouse at dose levels of up to 20 times the human dose. Pregnancy Teratogenic Effects. Pregnancy Category B Reproduction studies have been performed in rats, mice and rabbits at doses up to 20 times the human dose, and have revealed no evidence of impaired fertility or harm to the fetus due to cyclobenzaprine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk. Because cyclobenzaprine is closely related to the tricyclic antidepressants, some of which are known to be excreted in human milk, caution should be exercised when cyclobenzaprine hydrochloride is administered to a nursing woman. Pediatric Use Safety and effectiveness of cyclobenzaprine in pediatric patients below 15 years of age have not been established. Use in the Elderly The plasma concentration of cyclobenzaprine is increased in the elderly (see CLINICAL PHARMACOLOGY: Pharmacokinetics: Elderly ). The elderly may also be more at risk for CNS adverse events such as hallucinations and confusion, cardiac events resulting in falls or other sequelae, drug-drug and drug-disease interactions. For these reasons, in the elderly, cyclobenzaprine should be used only if clearly needed. In such patients cyclobenzaprine hydrochloride should be initiated with a 5 mg dose and titrated slowly upward."],"how_supplied":["HOW SUPPLIED Cyclobenzaprine Hydrochloride Tablets, USP are available containing 5 mg of cyclobenzaprine hydrochloride, USP. The 5 mg tablets are butter scotch yellow film-coated, round tablets debossed with 020 on one side and plain on other side. They are available as follows: NDC 60760-766-04 BOTTLES OF 4 NDC 60760-766-15 BOTTLES OF 15 NDC 60760-766-30 BOTTLES OF 30 NDC 60760-766-90 BOTTLES OF 90 Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature.] Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure."],"effective_time":"20251205","adverse_reactions":["ADVERSE REACTIONS Incidence of most common adverse reactions in the two double-blind*, placebo-controlled 5 mg studies (incidence of > 3% on cyclobenzaprine hydrochloride 5 mg): Cyclobenzaprine Hydrochloride 5 mg Cyclobenzaprine Hydrochloride 10 mg Placebo N = 464 N = 249 N = 469 Drowsiness 29% 38% 10% Dry Mouth 21% 32% 7% Fatigue 6% 6% 3% Headache 5% 5% 8% *Note: Cyclobenzaprine hydrochloride 10 mg data are from one clinical trial. Cyclobenzaprine hydrochloride 5 mg and placebo data are from two studies. Adverse reactions which were reported in 1% to 3% of the patients were: abdominal pain, acid regurgitation, constipation, diarrhea, dizziness, nausea, irritability, mental acuity decreased, nervousness, upper respiratory infection, and pharyngitis. The following list of adverse reactions is based on the experience in 473 patients treated with cyclobenzaprine hydrochloride 10 mg in additional controlled clinical studies, 7,607 patients in the postmarketing surveillance program, and reports received since the drug was marketed. The overall incidence of adverse reactions among patients in the surveillance program was less than the incidence in the controlled clinical studies. The adverse reactions reported most frequently with cyclobenzaprine were drowsiness, dry mouth and dizziness. The incidence of these common adverse reactions was lower in the surveillance program than in the controlled clinical studies: Clinical Studies with Cyclobenzaprine hydrochloride 10 mg Surveillance Program with Cyclobenzaprine hydrochloride 10 mg Drowsiness 39% 16% Dry Mouth 27% 7% Dizziness 11% 3% Among the less frequent adverse reactions, there was no appreciable difference in incidence in controlled clinical studies or in the surveillance program. Adverse reactions which were reported in 1% to 3% of the patients were: fatigue/tiredness, asthenia, nausea, constipation, dyspepsia, unpleasant taste, blurred vision, headache, nervousness, and confusion. The following adverse reactions have been reported in postmarketing experience or with an incidence of less than 1% of patients in clinical trials with the 10 mg tablet: Body as a Whole: Syncope; malaise. Cardiovascular: Tachycardia; arrhythmia; vasodilatation; palpitation; hypotension. Digestive: Vomiting; anorexia; diarrhea; gastrointestinal pain; gastritis; thirst; flatulence; edema of the tongue; abnormal liver function and rare reports of hepatitis, jaundice and cholestasis. Hypersensitivity: Anaphylaxis; angioedema; pruritus; facial edema; urticaria; rash. Musculoskeletal: Local weakness. Nervous System and Psychiatric: Seizures; ataxia; vertigo; dysarthria; tremors; hypertonia; convulsions; muscle twitching; disorientation; insomnia; depressed mood; abnormal sensations; anxiety; agitation; psychosis; abnormal thinking and dreaming; hallucinations; excitement; paresthesia; diplopia, serotonin syndrome. Skin: Sweating. Special Senses: Ageusia; tinnitus. Urogenital: Urinary frequency and/or retention. Causal Relationship Unknown Other reactions, reported rarely for cyclobenzaprine under circumstances where a causal relationship could not be established or reported for other tricyclic drugs, are listed to serve as alerting information to physicians: Body as a Whole: Chest pain; edema. Cardiovascular: Hypertension; myocardial infarction; heart block; stroke. Digestive: Paralytic ileus; tongue discoloration; stomatitis; parotid swelling. Endocrine: Inappropriate ADH syndrome. Hematic and Lymphatic: Purpura; bone marrow depression; leukopenia; eosinophilia; thrombocytopenia. Metabolic, Nutritional and Immune: Elevation and lowering of blood sugar levels; weight gain or loss. Musculoskeletal: Myalgia. Nervous System and Psychiatric: Decreased or increased libido; abnormal gait; delusions; aggressive behavior; paranoia; peripheral neuropathy; Bell's palsy; alteration in EEG patterns; extrapyramidal symptoms. Respiratory: Dyspnea. Skin: Photosensitization; alopecia. Urogenital: Impaired urination; dilatation of urinary tract; impotence; testicular swelling; gynecomastia; breast enlargement; galactorrhea."],"contraindications":["CONTRAINDICATIONS Hypersensitivity to any component of this product. Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis seizures and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs. Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure. Hyperthyroidism."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Cyclobenzaprine hydrochloride relieves skeletal muscle spasm of local origin without interfering with muscle function. It is ineffective in muscle spasm due to central nervous system disease. Cyclobenzaprine reduced or abolished skeletal muscle hyperactivity in several animal models. Animal studies indicate that cyclobenzaprine does not act at the neuromuscular junction or directly on skeletal muscle. Such studies show that cyclobenzaprine acts primarily within the central nervous system at brain stem as opposed to spinal cord levels, although its action on the latter may contribute to its overall skeletal muscle relaxant activity. Evidence suggests that the net effect of cyclobenzaprine is a reduction of tonic somatic motor activity, influencing both gamma (γ) and alpha (α) motor systems. Pharmacological studies in animals showed a similarity between the effects of cyclobenzaprine and the structurally related tricyclic antidepressants, including reserpine antagonism, norepinephrine potentiation, potent peripheral and central anticholinergic effects, and sedation. Cyclobenzaprine caused slight to moderate increase in heart rate in animals. Pharmacokinetics Estimates of mean oral bioavailability of cyclobenzaprine range from 33% to 55%. Cyclobenzaprine exhibits linear pharmacokinetics over the dose range 2.5 mg to 10 mg, and is subject to enterohepatic circulation. It is highly bound to plasma proteins. Drug accumulates when dosed 3 times a day, reaching steady-state within 3 to 4 days at plasma concentrations about 4-fold higher than after a single dose. At steady-state in healthy subjects receiving 10 mg t.i.d. (n = 18), peak plasma concentration was 25.9 ng/mL (range, 12.8 to 46.1 ng/mL), and area under the concentration-time (AUC) curve over an 8-hour dosing interval was 177 ng·hr/mL (range, 80 to 319 ng·hr/mL). Cyclobenzaprine is extensively metabolized, and is excreted primarily as glucuronides via the kidney. Cytochromes P450 3A4, 1A2, and, to a lesser extent, 2D6, mediate N-demethylation, one of the oxidative pathways for cyclobenzaprine. Cyclobenzaprine is eliminated quite slowly, with an effective half-life of 18 hours (range 8 to 37 hours; n = 18); plasma clearance is 0.7 L/min. The plasma concentration of cyclobenzaprine is generally higher in the elderly and in patients with hepatic impairment (see PRECAUTIONS: Use in the Elderly and PRECAUTIONS: Impaired Hepatic Function ). Elderly In a pharmacokinetic study in elderly individuals (≥ 65 yrs old), mean (n = 10) steady-state cyclobenzaprine AUC values were approximately 1.7-fold (171 ng·hr/mL, range 96.1 to 255.3) higher than those seen in a group of 18 younger adults (101.4 ng·hr/mL, range 36.1 to 182.9) from another study. Elderly male subjects had the highest observed mean increase, approximately 2.4-fold (198.3 ng·hr/mL, range 155.6 to 255.3 vs. 83.2 ng·hr/mL, range 41.1 to 142.5 for younger males) while levels in elderly females were increased to a much lesser extent, approximately 1.2-fold (143.8 ng·hr/mL, range 96.1 to 196.3 vs. 115.9 ng·hr/mL, range 36.1 to 182.9 for younger females). In light of these findings, therapy with cyclobenzaprine in the elderly should be initiated with a 5 mg dose and titrated slowly upward. Hepatic Impairment In a pharmacokinetic study of 16 subjects with hepatic impairment (15 mild, 1 moderate per Child-Pugh score), both AUC and C max were approximately double the values seen in the healthy control group. Based on the findings, cyclobenzaprine should be used with caution in subjects with mild hepatic impairment starting with the 5 mg dose and titrating slowly upward. Due to the lack of data in subjects with more severe hepatic insufficiency, the use of cyclobenzaprine in subjects with moderate to severe impairment is not recommended. No significant effect on plasma levels or bioavailability of cyclobenzaprine or aspirin was noted when single or multiple doses of the two drugs were administered concomitantly. Concomitant administration of cyclobenzaprine and naproxen or diflunisal was well tolerated with no reported unexpected adverse effects. However combination therapy of cyclobenzaprine with naproxen was associated with more side effects than therapy with naproxen alone, primarily in the form of drowsiness. No well controlled studies have been performed to indicate that cyclobenzaprine enhances the clinical effect of aspirin or other analgesics, or whether analgesics enhance the clinical effect of cyclobenzaprine in acute musculoskeletal conditions. Clinical Studies Eight double-blind controlled clinical studies were performed in 642 patients comparing cyclobenzaprine hydrochloride 10 mg, diazepam, and placebo. Muscle spasm, local pain and tenderness, limitation of motion, and restriction in activities of daily living were evaluated. In three of these studies there was a significantly greater improvement with cyclobenzaprine than with diazepam, while in the other studies the improvement following both treatments was comparable. Although the frequency and severity of adverse reactions observed in patients treated with cyclobenzaprine were comparable to those observed in patients treated with diazepam, dry mouth was observed more frequently in patients treated with cyclobenzaprine and dizziness more frequently in those treated with diazepam. The incidence of drowsiness, the most frequent adverse reaction, was similar with both drugs. The efficacy of cyclobenzaprine hydrochloride 5 mg was demonstrated in two 7-day, double-blind, controlled clinical trials enrolling 1,405 patients. One study compared cyclobenzaprine hydrochloride 5 mg and 10 mg t.i.d. to placebo; and a second study compared cyclobenzaprine hydrochloride 5 mg and 2.5 mg t.i.d. to placebo. Primary endpoints for both trials were determined by patient-generated data and included global impression of change, medication helpfulness, and relief from starting backache. Each endpoint consisted of a score on a 5-point rating scale (from 0 or worst outcome to 4 or best outcome). Secondary endpoints included a physician's evaluation of the presence and extent of palpable muscle spasm. Comparisons of cyclobenzaprine hydrochloride 5 mg and placebo groups in both trials established the statistically significant superiority of the 5 mg dose for all three primary endpoints at day 8 and, in the study comparing 5 mg and 10 mg, at day 3 or 4 as well. A similar effect was observed with cyclobenzaprine hydrochloride 10 mg (all endpoints). Physician-assessed secondary endpoints also showed that cyclobenzaprine hydrochloride 5 mg was associated with a greater reduction in palpable muscle spasm than placebo. Analysis of the data from controlled studies shows that cyclobenzaprine produces clinical improvement whether or not sedation occurs. Surveillance Program A post-marketing surveillance program was carried out in 7,607 patients with acute musculoskeletal disorders, and included 297 patients treated with cyclobenzaprine hydrochloride 10 mg for 30 days or longer. The overall effectiveness of cyclobenzaprine was similar to that observed in the double-blind controlled studies; the overall incidence of adverse effects was less ( see ADVERSE REACTIONS )."],"indications_and_usage":["INDICATIONS AND USAGE Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy."],"adverse_reactions_table":["<table ID=\"ID17\" width=\"100%\" styleCode=\"Noautorules\"><col width=\"18%\"/><col width=\"31%\"/><col width=\"33%\"/><col width=\"13%\"/><tbody><tr><td align=\"left\" styleCode=\" Toprule\" valign=\"top\">  </td><td align=\"left\" styleCode=\" Toprule\" valign=\"top\">Cyclobenzaprine   Hydrochloride 5 mg  </td><td align=\"left\" styleCode=\" Toprule\" valign=\"top\">Cyclobenzaprine   Hydrochloride 10 mg  </td><td align=\"left\" styleCode=\" Toprule\" valign=\"top\">Placebo  </td></tr><tr><td align=\"left\" valign=\"top\">  </td><td align=\"left\" valign=\"top\">N = 464  </td><td align=\"left\" valign=\"top\">N = 249  </td><td align=\"left\" valign=\"top\">N = 469  </td></tr><tr><td align=\"left\" valign=\"top\">Drowsiness  </td><td align=\"left\" valign=\"top\">29%  </td><td align=\"left\" valign=\"top\">38%  </td><td align=\"left\" valign=\"top\">10%  </td></tr><tr><td align=\"left\" valign=\"top\">Dry Mouth  </td><td align=\"left\" valign=\"top\">21%  </td><td align=\"left\" valign=\"top\">32%  </td><td align=\"left\" valign=\"top\">7%  </td></tr><tr><td align=\"left\" valign=\"top\">Fatigue  </td><td align=\"left\" valign=\"top\">6%  </td><td align=\"left\" valign=\"top\">6%  </td><td align=\"left\" valign=\"top\">3%  </td></tr><tr><td align=\"left\" styleCode=\" Botrule\" valign=\"top\">Headache  </td><td align=\"left\" styleCode=\" Botrule\" valign=\"top\">5%  </td><td align=\"left\" styleCode=\" Botrule\" valign=\"top\">5%  </td><td align=\"left\" styleCode=\" Botrule\" valign=\"top\">8%  </td></tr></tbody></table>","<table ID=\"ID19\" width=\"100%\" styleCode=\"Noautorules\"><col width=\"19%\"/><col width=\"40%\"/><col width=\"39%\"/><tbody><tr><td styleCode=\" Toprule\"/><td align=\"left\" styleCode=\" Toprule\">Clinical Studies with   Cyclobenzaprine   hydrochloride 10 mg  </td><td align=\"left\" styleCode=\" Toprule\">Surveillance Program with   Cyclobenzaprine   hydrochloride 10 mg  </td></tr><tr><td align=\"left\">Drowsiness  </td><td align=\"left\">39%  </td><td align=\"left\">16%  </td></tr><tr><td align=\"left\">Dry Mouth  </td><td align=\"left\">27%  </td><td align=\"left\">7%  </td></tr><tr><td align=\"left\" styleCode=\" Botrule\">Dizziness  </td><td align=\"left\" styleCode=\" Botrule\">11%  </td><td align=\"left\" styleCode=\" Botrule\">3%  </td></tr></tbody></table>"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION For most patients, the recommended dose of cyclobenzaprine hydrochloride tablets is 5 mg three times a day. Based on individual patient response, the dose may be increased to 10 mg three times a day. Use of cyclobenzaprine hydrochloride tablets for periods longer than 2 or 3 weeks is not recommended (see INDICATIONS AND USAGE) . Less frequent dosing should be considered for hepatically impaired or elderly patients (see PRECAUTIONS: Impaired Hepatic Function , and Use in the Elderly)."],"drug_abuse_and_dependence":["DRUG ABUSE AND DEPENDENCE Pharmacologic similarities among the tricyclic drugs require that certain withdrawal symptoms be considered when cyclobenzaprine is administered, even though they have not been reported to occur with this drug. Abrupt cessation of treatment after prolonged administration rarely may produce nausea, headache, and malaise. These are not indicative of addiction."],"spl_product_data_elements":["CYCLOBENZAPRINE HYDROCHLORIDE cyclobenzaprine hydrochloride ANHYDROUS LACTOSE CELLULOSE, MICROCRYSTALLINE CROSPOVIDONE (15 MPA.S AT 5%) D&C YELLOW NO. 10 FD&C BLUE NO. 2 FD&C YELLOW NO. 6 HYPROMELLOSE, UNSPECIFIED MAGNESIUM STEARATE POLYETHYLENE GLYCOL 400 POLYSORBATE 80 SILICON DIOXIDE STARCH, CORN TITANIUM DIOXIDE CYCLOBENZAPRINE HYDROCHLORIDE CYCLOBENZAPRINE butter scotch 020"],"package_label_principal_display_panel":["766-15"]},"tags":[{"label":"Muscle Relaxant","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histamine H1 receptor","category":"target"},{"label":"HRH1","category":"gene"},{"label":"CHRM3","category":"gene"},{"label":"HTR2A","category":"gene"},{"label":"M03BX08","category":"atc"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Spasticity","category":"indication"},{"label":"Approved 1970s","category":"decade"},{"label":"Antidepressive Agents","category":"pharmacology"},{"label":"Antidepressive Agents, Tricyclic","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Muscle Relaxants, Central","category":"pharmacology"},{"label":"Neuromuscular Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"4917 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"3853 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"3479 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"3342 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"3322 reports"},{"date":"","signal":"CHRONIC KIDNEY DISEASE","source":"FDA FAERS","actionTaken":"2766 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"2742 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"2450 reports"},{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"2358 reports"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"2341 reports"}],"drugInteractions":[{"url":"/drug/fluoxetine","drug":"fluoxetine","action":"Monitor closely","effect":"May interact with Fluoxetine","source":"DrugCentral","drugSlug":"fluoxetine"},{"url":"/drug/paroxetine","drug":"paroxetine","action":"Monitor closely","effect":"May interact with Paroxetine","source":"DrugCentral","drugSlug":"paroxetine"},{"url":"/drug/phenelzine","drug":"phenelzine","action":"Avoid combination","effect":"May interact with Phenelzine","source":"DrugCentral","drugSlug":"phenelzine"},{"url":"/drug/rasagiline","drug":"rasagiline","action":"Avoid combination","effect":"May interact with Rasagiline","source":"DrugCentral","drugSlug":"rasagiline"},{"url":"/drug/tramadol","drug":"tramadol","action":"Monitor closely","effect":"May interact with Tramadol Hydrochloride","source":"DrugCentral","drugSlug":"tramadol"},{"url":"/drug/tranylcypromine","drug":"tranylcypromine","action":"Avoid combination","effect":"May interact with Tranylcypromine","source":"DrugCentral","drugSlug":"tranylcypromine"}],"commonSideEffects":[{"effect":"Dry mouth","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Dizziness","drugRate":"6%","severity":"common","_validated":true},{"effect":"Nausea","drugRate":"3%","severity":"common","_validated":true},{"effect":"Dyspepsia","drugRate":"4%","severity":"common","_validated":true},{"effect":"Fatigue","drugRate":"3%","severity":"common","_validated":true},{"effect":"Somnolence","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Constipation","drugRate":"3%","severity":"common","_validated":true},{"effect":"Vomiting","drugRate":"reported","severity":"unknown"},{"effect":"Anorexia","drugRate":"reported","severity":"unknown"},{"effect":"Diarrhea","drugRate":"reported","severity":"unknown"},{"effect":"Gastrointestinal pain","drugRate":"reported","severity":"unknown"},{"effect":"Gastritis","drugRate":"reported","severity":"unknown"},{"effect":"Thirst","drugRate":"reported","severity":"unknown"},{"effect":"Flatulence","drugRate":"reported","severity":"unknown"},{"effect":"Edema of the tongue","drugRate":"reported","severity":"unknown"},{"effect":"Abnormal liver function","drugRate":"reported","severity":"unknown"},{"effect":"Hepatitis","drugRate":"reported","severity":"unknown"},{"effect":"Jaundice","drugRate":"reported","severity":"unknown"},{"effect":"Cholestasis","drugRate":"reported","severity":"unknown"},{"effect":"Paralytic ileus","drugRate":"reported","severity":"unknown"},{"effect":"Tongue discoloration","drugRate":"reported","severity":"unknown"},{"effect":"Stomatitis","drugRate":"reported","severity":"unknown"},{"effect":"Parotid swelling","drugRate":"reported","severity":"unknown"},{"effect":"Purpura","drugRate":"reported","severity":"unknown"},{"effect":"Bone marrow depression","drugRate":"reported","severity":"unknown"},{"effect":"Leukopenia","drugRate":"reported","severity":"unknown"},{"effect":"Eosinophilia","drugRate":"reported","severity":"unknown"},{"effect":"Thrombocytopenia","drugRate":"reported","severity":"unknown"},{"effect":"Anaphylaxis","drugRate":"reported","severity":"unknown"},{"effect":"Angioedema","drugRate":"reported","severity":"unknown"}],"contraindications":["Chronic heart failure","Conduction disorder of the heart","Glaucoma","Heart block","Hepatic failure","Hyperthyroidism","Myocardial infarction in recovery phase","Open-angle glaucoma","Retention of urine","Sinus tachycardia"],"specialPopulations":{"Pregnancy":"Pregnancy Category B. Reproduction studies have been performed in rats, mice and rabbits at doses up to 20 times the human dose, and have revealed no evidence of impaired fertility or harm to the fetus due to cyclobenzaprine hydrochloride. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.","Geriatric use":"The plasma concentration of cyclobenzaprine is increased in the elderly (see CLINICAL PHARMACOLOGY, Pharmacokinetics, Elderly). The elderly may also be more at risk for CNS adverse events such as hallucinations and confusion, cardiac events resulting in falls or other sequelae, drug-drug and drug-disease interactions. For these reasons, in the elderly, cyclobenzaprine should be used only if clearly needed. In such patients cyclobenzaprine hydrochloride should be initiated with 5 mg dose and titrated slowly upward.","Paediatric use":"Safety and effectiveness of Cyclobenzaprine Hydrochloride in pediatric patients below 15 years of age have not been established."}},"trials":[],"aliases":[],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0225/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$8","description":"CYCLOBENZAPRINE 10 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CYCLOBENZAPRINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:34:35.325989+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:34:40.938044+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:34:34.448713+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CYCLOBENZAPRINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:34:41.394483+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:34:26.400866+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:34:26.400890+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:34:42.975730+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Serotonin 2c (5-HT2c) receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:34:42.463110+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200636/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:34:42.111866+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA208170","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:34:26.400893+00:00"}},"allNames":"amrix","offLabel":[],"synonyms":["cyclobenzaprine","proheptatrien","proheptatriene","cyclobenzaprine hydrochloride","cyclobenzaprine HCl"],"timeline":[{"date":"1977-08-26","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"2007-02-01","type":"positive","source":"FDA Orange Book","milestone":"Amrix approved — 15MG"},{"date":"2008-04-18","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 12 manufacturers approved"},{"date":"2025-08-15","type":"positive","source":"FDA Orange Book","milestone":"Tonmya approved — 2.8MG"}],"aiSummary":"Amrix (CYCLOBENZAPRINE) is a small molecule muscle relaxant that targets the histamine H1 receptor. Originally developed and currently owned by Janssen Research and Development, it was FDA-approved in 1977 for the treatment of spasticity. As an off-patent medication, Amrix is available from multiple generic manufacturers. Key safety considerations include its 18-hour half-life and 55% bioavailability. Amrix is a valuable option for managing spasticity, with a well-established commercial status.","approvals":[{"date":"1977-08-26","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Amrix","ecosystem":[{"indication":"Spasticity","otherDrugs":[{"name":"caffeine","slug":"caffeine","company":"Novartis"},{"name":"carisoprodol","slug":"carisoprodol","company":"Meda Pharms"},{"name":"chlorphenesin carbamate","slug":"chlorphenesin-carbamate","company":"Pharmacia And Upjohn"},{"name":"chlorzoxazone","slug":"chlorzoxazone","company":"Janssen R And D"}],"globalPrevalence":null}],"mechanism":{"target":"Histamine H1 receptor","novelty":"Follow-on","targets":[{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"},{"gene":"CHRM3","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M3","protein":"Muscarinic acetylcholine receptor M3"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"SLC6A2","source":"DrugCentral","target":"Sodium-dependent noradrenaline transporter","protein":"Sodium-dependent noradrenaline transporter"},{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"CHRM2","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M2","protein":"Muscarinic acetylcholine receptor M2"},{"gene":"SLC6A4","source":"DrugCentral","target":"Sodium-dependent serotonin transporter","protein":"Sodium-dependent serotonin transporter"},{"gene":"CHRM1","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M1","protein":"Muscarinic acetylcholine receptor M1"},{"gene":"HTR6","source":"DrugCentral","target":"5-hydroxytryptamine receptor 6","protein":"5-hydroxytryptamine receptor 6"},{"gene":"HTR7","source":"DrugCentral","target":"5-hydroxytryptamine receptor 7","protein":"5-hydroxytryptamine receptor 7"}],"modality":"Small Molecule","drugClass":"Muscle Relaxant","explanation":"","oneSentence":"","technicalDetail":"Cyclobenzaprine exerts its muscle relaxant effects by competitively antagonizing the histamine H1 receptor, which is involved in the regulation of muscle tone and contraction."},"commercial":{"launchDate":"1977","_launchSource":"DrugCentral (FDA 1977-08-26, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/751","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CYCLOBENZAPRINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CYCLOBENZAPRINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:24:39.778634","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:34:45.103288+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"baclofen","drugSlug":"baclofen","fdaApproval":"1977-11-22","patentExpiry":"Sep 8, 2037","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tizanidine","drugSlug":"tizanidine","fdaApproval":"1996-11-27","patentExpiry":"May 7, 2042","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"cyclobenzaprine","indications":{"approved":[{"name":"Spasticity","source":"DrugCentral","snomedId":221360009,"regulator":"FDA","eligibility":"Children with cerebral palsy, spasticity associated with cerebral or spinal cord disease"}],"offLabel":[{"name":"Fibromyalgia","source":"DrugCentral","drugName":"CYCLOBENZAPRINE","evidenceCount":61,"evidenceLevel":"strong"}],"pipeline":[]},"currentOwner":"Janssen Res And Dev","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"baclofen","brandName":"baclofen","genericName":"baclofen","approvalYear":"1977","relationship":"same-class"},{"drugId":"tizanidine","brandName":"tizanidine","genericName":"tizanidine","approvalYear":"1996","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07464535","phase":"PHASE1","title":"A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2022-03-18","conditions":["Healthy Subjects (HS)"],"enrollment":20,"completionDate":"2022-04-30"},{"nctId":"NCT07404397","phase":"PHASE2,PHASE3","title":"Comparing Adjuvant Treatments for High Tone Pelvic Floor Dysfunction","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2026-02-18","conditions":["High Tone Pelvic Floor Dysfunction"],"enrollment":60,"completionDate":"2026-12"},{"nctId":"NCT07413367","phase":"PHASE1","title":"A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2025-12-09","conditions":["Pharmakokinetic","Open Label","Phase 1"],"enrollment":50,"completionDate":"2026-02-10"},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":["Lactating Women on Select DOI","Breastfed Infants of Mothers on Select DOI"],"enrollment":1600,"completionDate":"2027-07-31"},{"nctId":"NCT04240626","phase":"PHASE4","title":"Multimodal Analgesia Effect on Post Surgical Patient","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Davis","startDate":"2021-01-20","conditions":["Obesity, Morbid","Surgery","Bariatric Surgery Candidate"],"enrollment":60,"completionDate":"2026-06-24"},{"nctId":"NCT06636786","phase":"PHASE2","title":"Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-03-25","conditions":["Acute Stress Reaction","Acute Stress Disorder","Neurocognitive Function","Post-traumatic Stress"],"enrollment":180,"completionDate":"2025-09"},{"nctId":"NCT02202369","phase":"PHASE4","title":"Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study","status":"SUSPENDED","sponsor":"OrthoCarolina Research Institute, Inc.","startDate":"2015-06-25","conditions":["Single Level Lumbar Decompression and Fusion Spine Surgery"],"enrollment":50,"completionDate":"2050-12-31"},{"nctId":"NCT06894472","phase":"NA","title":"A Comparative Study of EMG Biofeedback and Pharmacotherapy for the Treatment of Masticatory Muscle Hyperactivity in Bruxism Patients","status":"NOT_YET_RECRUITING","sponsor":"Beni-Suef University","startDate":"2025-03-26","conditions":["Bruxism"],"enrollment":30,"completionDate":"2025-05-01"},{"nctId":"NCT02829814","phase":"PHASE3","title":"Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia","status":"TERMINATED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2016-07-22","conditions":["Fibromyalgia","Myofascial Pain Syndromes","Muscular Diseases","Nervous System Diseases","Neuromuscular Diseases","Rheumatic Diseases","Musculoskeletal Diseases"],"enrollment":51,"completionDate":"2016-09-13"},{"nctId":"NCT02589275","phase":"PHASE3","title":"A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2015-08-04","conditions":["Primary Fibromyalgia"],"enrollment":375,"completionDate":"2016-09-28"},{"nctId":"NCT02651324","phase":"PHASE4","title":"Efficacy of Ketamine for Improvement in Postoperative Pain Control After Spinal Fusion for Idiopathic Scoliosis","status":"COMPLETED","sponsor":"Albany Medical College","startDate":"2013-05","conditions":["Idiopathic Scoliosis","Post-operative Pain"],"enrollment":50,"completionDate":"2017-12"},{"nctId":"NCT02436096","phase":"PHASE3","title":"A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2015-04","conditions":["Fibromyalgia","Myofascial Pain Syndromes","Muscular Diseases","Musculoskeletal Diseases","Nervous System Diseases","Neuromuscular Diseases","Rheumatic Diseases"],"enrollment":519,"completionDate":"2016-09"},{"nctId":"NCT02421679","phase":"PHASE2","title":"Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2015-04-14","conditions":["PTSD"],"enrollment":159,"completionDate":"2016-05-26"},{"nctId":"NCT03110575","phase":"PHASE3","title":"12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients","status":"TERMINATED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2017-06-20","conditions":["PTSD"],"enrollment":190,"completionDate":"2018-07-27"},{"nctId":"NCT03841773","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD","status":"TERMINATED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2019-03-07","conditions":["PTSD"],"enrollment":192,"completionDate":"2020-04-24"},{"nctId":"NCT03508700","phase":"PHASE3","title":"A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2018-04-19","conditions":["PTSD"],"enrollment":93,"completionDate":"2019-09-30"},{"nctId":"NCT05273749","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2022-04-06","conditions":["Fibromyalgia"],"enrollment":457,"completionDate":"2023-11-14"},{"nctId":"NCT01041495","phase":"PHASE4","title":"Cyclobenzaprine Extended Release (ER) for Fibromyalgia","status":"TERMINATED","sponsor":"State University of New York - Upstate Medical University","startDate":"2009-06","conditions":["Fibromyalgia","Pain","Sleep","Fatigue"],"enrollment":37,"completionDate":"2013-03"},{"nctId":"NCT03062540","phase":"PHASE3","title":"Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD","status":"TERMINATED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2017-03-27","conditions":["PTSD"],"enrollment":358,"completionDate":"2018-07-27"},{"nctId":"NCT05683574","phase":"PHASE3","title":"Fixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-05-30","conditions":["Third Molar Extraction"],"enrollment":0,"completionDate":"2028-02-28"},{"nctId":"NCT04990804","phase":"PHASE4","title":"Opioid Free vs. Standard Perioperative Pain Regimen for Anterior Cervical Discectomy and Fusion (ACDF) Surgery","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2021-08-01","conditions":["Opioid Use","Spinal Diseases","Surgery--Complications","Surgery","Postoperative Pain"],"enrollment":8,"completionDate":"2022-02-01"},{"nctId":"NCT04508621","phase":"PHASE3","title":"A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2020-07-22","conditions":["Fibromyalgia"],"enrollment":514,"completionDate":"2021-11-01"},{"nctId":"NCT05372887","phase":"PHASE2","title":"Safety and Efficacy Study of TNX-102 SL in Participants With PTSD","status":"WITHDRAWN","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2022-10-14","conditions":["PTSD"],"enrollment":0,"completionDate":"2022-11-08"},{"nctId":"NCT04771741","phase":"","title":"Opiate Free Multimodal Pain Pathway in Elective Foot and Ankle Surgery: A Prospective Study","status":"COMPLETED","sponsor":"Prisma Health-Midlands","startDate":"2020-12-01","conditions":["Bunion of Unspecified Foot","Bunionette of Unspecified Foot","Hammertoe","Ankle Fractures","Achilles Tendon Surgery"],"enrollment":72,"completionDate":"2023-04-26"},{"nctId":"NCT03127592","phase":"PHASE3","title":"Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction","status":"TERMINATED","sponsor":"Apsen Farmaceutica S.A.","startDate":"2020-10-05","conditions":["Pain, Acute"],"enrollment":140,"completionDate":"2022-07-26"},{"nctId":"NCT04172831","phase":"PHASE3","title":"A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2019-12-09","conditions":["Fibromyalgia"],"enrollment":503,"completionDate":"2020-10-29"},{"nctId":"NCT04407377","phase":"PHASE1","title":"Effects of Tolperisone on Measures of Drowsiness and Cognitive Function","status":"COMPLETED","sponsor":"Neurana Pharmaceuticals, Inc.","startDate":"2020-06-20","conditions":["Healthy"],"enrollment":39,"completionDate":"2021-03-31"},{"nctId":"NCT03353922","phase":"PHASE1","title":"Driving Simulation to Assess Non-Sedative Effects of Tolperisone","status":"COMPLETED","sponsor":"Neurana Pharmaceuticals, Inc.","startDate":"2017-07-31","conditions":["Driving Impaired"],"enrollment":35,"completionDate":"2018-01-30"},{"nctId":"NCT03025113","phase":"PHASE3","title":"Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine in Osteomuscular Treatment","status":"COMPLETED","sponsor":"EMS","startDate":"2018-03-08","conditions":["Musculoskeletal Pain"],"enrollment":416,"completionDate":"2020-03-27"},{"nctId":"NCT04704297","phase":"PHASE4","title":"Trigger Point Injection for Myofascial Pain Syndrome in the Low Back: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Madigan Army Medical Center","startDate":"2020-12-28","conditions":["Low Back Pain","Myofascial Pain Syndrome Lower Back"],"enrollment":180,"completionDate":"2022-07-01"},{"nctId":"NCT02862977","phase":"PHASE3","title":"Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine and Caffeine in Osteomuscular Treatment","status":"COMPLETED","sponsor":"EMS","startDate":"2017-11-10","conditions":["Musculoskeletal Pain"],"enrollment":414,"completionDate":"2019-12-20"},{"nctId":"NCT04164719","phase":"PHASE1","title":"Dose-Proportionality and Food Effect Study of TNX-102 SL","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2019-10-14","conditions":["Healthy Subjects"],"enrollment":16,"completionDate":"2019-12-24"},{"nctId":"NCT01490788","phase":"PHASE1","title":"A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults.","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2011-11-18","conditions":["Healthy"],"enrollment":30,"completionDate":"2011-12-30"},{"nctId":"NCT01081990","phase":"NA","title":"Use of Cyclobenzaprine After Vaginal Surgery","status":"COMPLETED","sponsor":"Endeavor Health","startDate":"2010-04","conditions":["Postoperative Pain"],"enrollment":63,"completionDate":"2014-08-01"},{"nctId":"NCT03168022","phase":"PHASE1","title":"Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers.","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2015-12-16","conditions":["Healthy Adults"],"enrollment":43,"completionDate":"2016-01-26"},{"nctId":"NCT00386243","phase":"NA","title":"Evaluation of Stepped Care for Chronic Pain in Iraq/Afghanistan Veterans (ESCAPE)","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2007-12","conditions":["Low Back Pain","Pain","Pain, Intractable"],"enrollment":242,"completionDate":"2012-09"},{"nctId":"NCT02497066","phase":"PHASE3","title":"Efficacy Study Comparing Compounded Topical Pain Creams vs. Placebo for Treating Pain Symptoms","status":"COMPLETED","sponsor":"Walter Reed National Military Medical Center","startDate":"2015-08-05","conditions":["Pain"],"enrollment":399,"completionDate":"2018-02-28"},{"nctId":"NCT02814565","phase":"PHASE3","title":"Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-10-12","conditions":["Neck Pain","Back Pain","Spasm"],"enrollment":180,"completionDate":"2017-03-14"},{"nctId":"NCT03207828","phase":"NA","title":"Testing Interventions for Patients With Fibromyalgia and Depression","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2017-09-09","conditions":["Fibromyalgia","Depression"],"enrollment":90,"completionDate":"2019-05-31"},{"nctId":"NCT01587274","phase":"PHASE4","title":"A Randomized Study of Three Medication Regimens for Acute Low Back Pain","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2012-04","conditions":["Acute Low Back Pain"],"enrollment":323,"completionDate":"2014-12"},{"nctId":"NCT03443960","phase":"PHASE1","title":"Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2018-01-29","conditions":["Healthy Subjects"],"enrollment":60,"completionDate":"2018-04-09"},{"nctId":"NCT02707094","phase":"NA","title":"A Pilot Study Examining the Efficacy of Biomodulator Treatment for Chronic Low Back Pain","status":"COMPLETED","sponsor":"Brooke Army Medical Center","startDate":"2013-01","conditions":["Chronic Low Back Pain"],"enrollment":75,"completionDate":"2016-08-31"},{"nctId":"NCT02403687","phase":"","title":"Prospective Analgesic Compound Efficacy (PACE) Study","status":"COMPLETED","sponsor":"Express Specialty Pharmacy","startDate":"2015-06","conditions":["Arthritis","Tendonitis","Gout","Radiculopathy","Muscle Spasms","Synovitis","Migraine","Headache"],"enrollment":300,"completionDate":"2017-02"},{"nctId":"NCT02642861","phase":"PHASE3","title":"Cyclobenzaprine in Muscle Cramps With Liver Cirrhosis","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2018-10","conditions":["Liver Cirrhosis"],"enrollment":200,"completionDate":"2019-12"},{"nctId":"NCT02015234","phase":"PHASE3","title":"12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2013-12","conditions":["Primary Fibromyalgia"],"enrollment":158,"completionDate":"2015-08"},{"nctId":"NCT00913419","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability of Cyclobenzaprine HCl Tablets","status":"COMPLETED","sponsor":"Sandoz","startDate":"1988-11","conditions":["Depression"],"enrollment":30,"completionDate":"1988-12"},{"nctId":"NCT01903265","phase":"PHASE2,PHASE3","title":"BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2013-09","conditions":["Primary Fibromyalgia"],"enrollment":205,"completionDate":"2014-09"},{"nctId":"NCT02974166","phase":"NA","title":"Analysis of the Effects of the Osteopathic Manipulative Treatment in Carriers of Temporomandibular Disorders","status":"COMPLETED","sponsor":"Instituto Brasileiro de Osteopatia","startDate":"2012-03","conditions":["Temporomandibular Disorder"],"enrollment":32,"completionDate":"2016-08"},{"nctId":"NCT01587508","phase":"PHASE3","title":"Study Comparing A New Drug Containing The Combination Meloxicam And Cyclobenzaprine In The Treatment Of Acute Lumbago","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2013-05","conditions":["Acute Lumbago"],"enrollment":0,"completionDate":"2013-05"},{"nctId":"NCT01921296","phase":"PHASE2","title":"Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients","status":"TERMINATED","sponsor":"Lynn Henry","startDate":"2013-08","conditions":["Sleep Initiation and Maintenance Disorders","Pain"],"enrollment":2,"completionDate":"2015-04"},{"nctId":"NCT01889173","phase":"PHASE1","title":"Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2013-06","conditions":["Healthy Adults"],"enrollment":24,"completionDate":"2014-03"},{"nctId":"NCT01689259","phase":"PHASE1","title":"Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2012-09","conditions":["Healthy Adults"],"enrollment":24,"completionDate":"2014-03"},{"nctId":"NCT01634412","phase":"PHASE1","title":"Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy Adults","status":"COMPLETED","sponsor":"Tonix Pharmaceuticals, Inc.","startDate":"2012-06","conditions":["Healthy Adults"],"enrollment":24,"completionDate":"2014-01"},{"nctId":"NCT01151787","phase":"PHASE3","title":"Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine","status":"TERMINATED","sponsor":"Kennedy Medical Group","startDate":"2010-07","conditions":["Chronic Migraine"],"enrollment":35,"completionDate":"2013-09"},{"nctId":"NCT00790270","phase":"PHASE2","title":"Comparison of Ibuprofen, Cyclobenzaprine, or Both for Acute Cervical Strain: A Randomized Clinical Trial","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2003-01","conditions":["Cervical Strain"],"enrollment":61,"completionDate":"2004-01"},{"nctId":"NCT01028014","phase":"NA","title":"Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2010-04","conditions":["Urethral Sphincter Activity"],"enrollment":56,"completionDate":"2011-04"},{"nctId":"NCT01421433","phase":"PHASE3","title":"A Comparative Study Between Lysine Clonixinate+Cyclobenzaprine and Caffeine+Carisoprodol+Sodium Diclofenac+Paracetamol","status":"UNKNOWN","sponsor":"Farmoquimica S.A.","startDate":"2012-05","conditions":["Low Back Pain"],"enrollment":160,"completionDate":"2013-01"},{"nctId":"NCT00246389","phase":"PHASE4","title":"An Effectiveness and Safety Study of Cyclobenzaprine HCl Alone or in Combination With Ibuprofen for Acute Back or Neck Muscle Pain With Muscle Spasm","status":"COMPLETED","sponsor":"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.","startDate":"","conditions":["Pain","Spasm"],"enrollment":1000,"completionDate":"2004-07"},{"nctId":"NCT00778037","phase":"NA","title":"Bioequivalence Study of Cyclobenzaprine Hydrochloride 10 mg Tablets, USP Under Fasting Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2006-09","conditions":["Healthy"],"enrollment":40,"completionDate":"2006-11"},{"nctId":"NCT00635037","phase":"NA","title":"Myofascial Pain:Acupuncture Versus Trigger Point Injection Combined With Dipyrone and Cyclobenzaprine","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2004-06","conditions":["Myofascial Pain Syndromes"],"enrollment":30,"completionDate":"2006-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule, Tablet","formulations":[{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"CYCLOBENZAPRINE HYDROCHLORIDE"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"Cyclobenzaprine Hydrochloride"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"AMRIX"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"Amrix"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"Cyclobenzaprine HCL ER"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"Cyclobenzaprine Hydrochloride"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"Cyclobenzaprine HCL ER"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"Cyclobenzaprine HCLER"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"Cyclobenzaprine Hydrochloride"},{"form":"CAPSULE, FILM COATED, EXTENDED RELEASE","route":"ORAL","productName":"Cyclobenzaprine Hydrochloride"},{"form":"CAPSULE, FILM COATED, EXTENDED RELEASE","route":"ORAL","productName":"Cyclobenzaprine Hydrochloride"},{"form":"TABLET","route":"ORAL","productName":"CYCLOBENZAPRINE HYDROCHLORIDE"},{"form":"TABLET","route":"ORAL","productName":"CYCLOBENZAPRINE HYROCHLORIDE"},{"form":"TABLET","route":"ORAL","productName":"Cyclobenzaprine Hydrochloride"},{"form":"TABLET","route":"ORAL","productName":"cyclobenzaprine hydrochloride"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147791","MMSL":"217","NDDF":"001678","UNII":"69O5WQQ5TI","VUID":"4019699","CHEBI":"CHEBI:3996","VANDF":"4017956","INN_ID":"791","RXNORM":"21949","UMLSCUI":"C0056732","chemblId":"CHEMBL1200636","ChEMBL_ID":"CHEMBL669","KEGG_DRUG":"D00772","DRUGBANK_ID":"DB00924","PUBCHEM_CID":"2895","SNOMEDCT_US":"373779004","IUPHAR_LIGAND_ID":"7152","SECONDARY_CAS_RN":"6202-23-9","MESH_SUPPLEMENTAL_RECORD_UI":"C004704"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Janssen Res And Dev","relationship":"Current Owner"}],"pharmacokinetics":{"source":"FDA label","halfLife":"18 hours","bioavailability":"55%","fractionUnbound":"0.012%"},"publicationCount":358,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"M03BX08","allCodes":["M03BX08"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 27","pmid":"41889332","title":"Superior Oblique Myokymia Treated with Cyclobenzaprine.","journal":"The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques"},{"date":"2026 Mar 10","pmid":"41822869","title":"Cyclobenzaprine Reimagined: Clinical Insights Into Tonmya for Fibromyalgia.","journal":"The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians"},{"date":"2026 Mar","pmid":"41749492","title":"Single-Dose Pharmacokinetic Assessment of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open-Label Studies in Healthy Volunteers.","journal":"Clinical pharmacology in drug development"},{"date":"2026 Mar","pmid":"41730795","title":"Maternal and Pediatric Precision in Therapeutic Knowledge Portal (MPRINT-KP): Landscape Analysis of Pharmacology Research in Maternal and Pediatric Patient Populations.","journal":"Pharmacotherapy"},{"date":"2006","pmid":"30000455","title":"Cyclobenzaprine.","journal":""}],"companionDiagnostics":[],"genericManufacturers":21,"_genericFilersChecked":true,"genericManufacturerList":["Actavis Labs Fl Inc","Aiping Pharm Inc","Apotex","Aurobindo Pharma","Chartwell Rx","Invagen Pharms","Jubilant Cadista","Kvk Tech","Macleods Pharms Ltd","Novast Labs","Oxford Pharms","Pliva","Prinston Inc","Rising","Rubicon Research","Sandoz","Sun Pharm Inds Ltd","Tp Anda Holdings","Twi Pharms Inc","Unichem","Watson Labs"],"status":"approved","companyName":"Janssen Res And Dev","companyId":"","modality":"Small molecule","firstApprovalDate":"1977","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1977-08-26T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2006-02-03T00:00:00.000Z","mah":"ACTAVIS LABS FL INC","brand_name_local":null,"application_number":"ANDA071611"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-08-07T00:00:00.000Z","mah":"PRINSTON INC","brand_name_local":null,"application_number":"ANDA077797"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-03-13T00:00:00.000Z","mah":"TWI PHARMS INC","brand_name_local":null,"application_number":"ANDA091281"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-07-06T00:00:00.000Z","mah":"UNICHEM","brand_name_local":null,"application_number":"ANDA213324"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-07-22T00:00:00.000Z","mah":"MACLEODS PHARMS LTD","brand_name_local":null,"application_number":"ANDA207314"},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:34:45.103288+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}